Vetter Once Again Named Best Managed Company
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has been named Best Managed Company in its anniversary year for the sixth time in a row. For 75 years, the family-owned company has stood for quality, responsibility, and a strong commitment to improving the quality of life of patients worldwide. The award demonstrates how Vetter pursues its strategic goals in a focused and action-driven manner. The jury recognizes the company's long-term thinking as a key success factor. The Best Managed Companies Award is organized by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung, and the Bundesverband der Deutschen Industrie e.V. (Federation of German Industries). The trophy and certificate were presented to the CDMO at an awards ceremony on May 22 at the Gesellschaftshaus Palmengarten in Frankfurt, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527162693/en/
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family (second from right) along with Vetter Managing Director Titus Ottinger (second from left), Holger Loesch, Deputy Director General of the Federation of German Industries (first from left) and moderator Susanne Schoene, at the presentation of the Best Managed Companies Award.
Markus Seiz, Best Managed Companies Program Lead and Director at Deloitte Private says: 'Vetter is an example of how critical it is for actions to align with core values in order to achieve economic success as a globally active family business. In our opinion, the trusted pharmaceutical service provider is one of the pioneers of sustainable and innovative corporate management in the way it combines its strategic vision and responsible business practices.'
To earn the Best Managed Companies Award, a company must convince the high-caliber jury across four key business areas known as 'value drivers,' including: strategy; productivity and innovation; culture and commitment; and governance and finance. After a personal coaching session, the participating companies answer an extensive and detailed questionnaire. In 2025, for the first time, the jury also evaluated criteria that are geared towards the specific values and unique profiles of family businesses. Vetter impressed in all four areas due to its consistency in driving forward and developing its projects and processes in line with its corporate values.
Vetter Managing Director Titus Ottinger emphasizes: 'Participating in the Best Managed Companies Award enables us to receive valuable feedback through a stringent external selection process. This feedback is very important for us, as it comes from experienced professionals in a wide range of fields, whose perspectives allow us to further grow. This year, we were able to show even more explicitly how deeply we have anchored the values of our family business in our day-to-day operations. This new facet of the program makes the award even more valuable to us.'
With 11% sales growth reaching 1.1 billion euros in 2024, Vetter demonstrates how its consistent focus on all four value drivers results in meaningful business outcomes. The results for 2024 are also positive in other areas. For example, the CDMO continued its growth in employment, now with 7,000 global employees. With investments of 269 million euros in the expansion and modernization of its sites in Germany, Austria, and the U.S., Vetter continues to invest in its dynamic and organic growth in the production of complex injectable drugs. In a politically and economically challenging environment, the CDMO is proving to be a secure employer and reliable partner for pharma and biotech companies worldwide.
The strategic focus of the company's development in 2024 was once again on the reliability and high-quality of the services offered, sustainable growth, and advancing digital transformation in all facets of the company. Numerous projects for the digitization of production processes and in the areas of AI, human-machine interaction, cloud and cyber security are currently underway or have already been completed. With a comprehensive innovation management process characterized by interactive formats, Vetter's employees prioritize identifying trends and technologies early on. For many years, the CDMO has placed a strategic focus on sustainability in the areas of ecology, economy, and social issues. The family-owned company published its fourth comprehensive sustainability report earlier this year.
The Vetter press kit and additional information are available in the digital press area.
About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of its more than 7,000 employees. In close partnership with its customers, the Vetter team supplies patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. The company is an industry pioneer in sustainability and a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received gold status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition as Best Managed Company emphasize Vetter's commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527162693/en/
CONTACT: Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg,
Germany
Phone: +49 (0)751-3700-3729
E-mail:[email protected]
KEYWORD: GERMANY EUROPE UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MANUFACTURING HEALTH PHARMACEUTICAL PACKAGING
SOURCE: Vetter Pharma International GmbH
Copyright Business Wire 2025.
PUB: 05/27/2025 08:24 AM/DISC: 05/27/2025 08:22 AM
http://www.businesswire.com/news/home/20250527162693/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ('Quantum BioPharma' or the 'Company'), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company's Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis (MS). To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk. Videos can be seen at Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibers. 'We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS,' said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit Forward-Looking Information This press release contains certain 'forward-looking statements' within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'may,' 'will,' 'potential,' 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements include the Company's belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStop's stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStop stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Contacts: Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@ (833) 571-1811 Investor Relations Investor Relations: IR@ Inquiries: info@ in to access your portfolio
Yahoo
2 days ago
- Yahoo
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art facility in Hopewell, New Jersey. This strategic expansion is designed to meet growing industry demand for high-quality viral vector production and reflects ProBio's ongoing commitment to supporting the advancement of life-changing gene therapies. The Hopewell facility is purpose-built to provide end-to-end AAV manufacturing solutions that align with global regulatory and quality standards. ProBio's new capabilities offer clients fully integrated services—including GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation and aseptic fill/finish—within a single U.S.-based location. This streamlined approach simplifies coordination, reduces handoffs, and accelerates timelines across the drug development lifecycle. "At ProBio, we recognize that every gene therapy program represents a critical opportunity to change lives," said Allen Guo, Chief Executive Officer of ProBio. "Our new GMP AAV manufacturing platform reflects our mission to help developers navigate complex manufacturing challenges with speed, precision, and scientific integrity." The Hopewell team brings decades of hands-on experience in biologics and viral vector manufacturing, with a track record of supporting the development and commercialization of approved therapies. "The launch of our GMP AAV services is the result of deep cross-functional collaboration and reflects our commitment to delivering high-quality, end-to-end solutions for our partners," said Michael Vreeland, US Site Head. "Our experts have built and scaled manufacturing systems for some of the industry's most advanced therapeutics, and they're now applying that same expertise and dedication to every program at ProBio." Key Features of ProBio's GMP AAV Manufacturing Services include: Scalable, Phase-Appropriate Manufacturing: Flexible batch sizes from 50L to 200L, with capability for 2x200L concurrent runs—supporting early clinical to late-phase programs. Fully Integrated Platform, Single-Site Solutions: From high-quality plasmid production and AAV vector manufacturing to final drug product fill/finish, ProBio streamlines the entire process under one roof—reducing complexity, saving time, and accelerating developer's path to clinic. Resilient U.S.-Based Supply Chain: By prioritizing domestic sourcing for key raw materials, ProBio ensures greater supply stability, faster lead times, and unwavering quality—empowering gene therapy developers to move forward with confidence. Accelerated Timelines Through In-House Analytics: Comprehensive internal QC and analytical capabilities enable fast, phase-appropriate release while maintaining the highest standards of precision and compliance. To enhance operational effectiveness and ensure seamless compliance, ProBio has embraced digitalization through the implementation of a fully electronic Quality Management System (QMS) powered by Veeva. This system enables real-time electronic approval and traceability of key GMP documentation, including batch records, deviations, change controls, and CAPA events—supporting both regulatory alignment and execution speed. "What differentiates our AAV platform is the combination of flexible manufacturing architecture and built-in quality by design," said Lance Marquardt, Director of AAV Manufacturing Operations at ProBio. "Our processes are engineered to support a wide range of serotypes, production scales, and clinical milestones—while ensuring rigorous in-process controls and regulatory alignment at every step." With this launch, ProBio continues to position itself as a strategic partner for gene therapy innovators—offering agile, phase-appropriate manufacturing solutions that evolve with the needs of each program. ABOUT PROBIO ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support. Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches. To learn more about ProBio services, please visit CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER. Media Contact:Alvin Jogasuria Head of Marketing, Americas and View original content to download multimedia: SOURCE ProBio Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
4 days ago
- Associated Press
Bora Pharmaceuticals 2Q25 Operating Margin Expanded 5 Percentage Points, Reaching Quarterly High Since The Start of Integration in 4Q24; Strong Momentum Poised to Accelerate in 2H25 As Operational Efficiency Gains Materialize
HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for second quarter of 2025. Quarterly Business and Financial Highlights · Company reported quarterly basic EPS of NT$5.95, with NT$1.81 from discontinued operations. OPEX was ~15% below guidance, aided by a ~4% FX gain. Gross margin was impacted by ~4% due to lower CDMO utilization. · FX loss totaled at ~NT$252 million in 2Q25, or NT$2.4 per share; Excluding FX impact from operational to non-OP, core EPS would have reached approximately NT$8.08, second highest on record after 1Q23, excluding all M&A related non-operating gains. · Fueled by expanded capacity and new dosage forms, Bora's CDMO business in 1H25, including internal orders, grew 69.5% compared to same period last year, reaching more than NT$5.01 billion, and yet posted a 26.6% sequential decline during the quarter due to slower momentum navigating through transitional integration phase mainly at sterile injectable site in Maryland and Zhunan facility with no impact on long-term fundamentals. · Pharma Sales revenues in 1H25 rose 23.0% YoY based on reported unaudited monthly sales, driven by market share expansion of the vigabatrin franchise across three dosage forms. VIGAFYDE uptake continued its acceleration during the quarter, supporting momentum into 2H25. · The Group observed robust CDMO order momentum in 3Q25, supported by a more streamlined and disciplined operating structure. With this solid execution base in place, Bora is confident that core profitability will resume. As CDMO growth accelerates through expanded U.S.-based capacity and capabilities in the near future, Bora shall be positioned for the next inflection point. · Share capital increased 0.25% during the quarter from employee stock option exercises and convertible bond conversions. Company went ex-rights on August 4 with book closure and record date both on August 10. · The Board approved setting up Bora Global Ltd., a wholly owned BVI subsidiary of Bora, and the injection of US$40mn in eye of fluctuating FX and other geo political nuances to reduce the Company's USD exposure. Mr. Bobby Sheng, Chairman of Bora Group, stated, 'The second quarter marks our transition out of the integration phase that began in 4Q24 with stronger operational cash inflow. To further enhance our resilience to geopolitical and currency fluctuations, we have confirmed the establishment of Bora Global Ltd., a wholly owned BVI subsidiary. The planned injection of US$40 million into this entity reflects a proactive step to reduce the Company's USD exposure and strengthen financial flexibility amid ongoing macro uncertainties. Following multiple business and capacity acquisitions last year, we are proud to have established a solid foundation for operational efficiency gains and scalable growth in our change-enabling CDMO business and service-model oriented specialty pharma expansion. Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by ample cash on hand to grow our CDMO business. As of 2Q25, around 80% of our 2025 CAPEX plan has been deployed. One of the key investments include a high-performance filling line at our Canada site in Mississauga which enables larger volumes at higher speeds with greater flexibility, particularly for dermatologic products. The investment comes as the global dermatology drugs market is projected to nearly double in value to over $70 billion by 2030, reflecting the rising demand for high-quality, specialized treatments. In addition, while Flex-Pro line at our sterile injectable site in Maryland is expected to enter commercial stage production in 3Q25, while state-of-the-art isolated fill-finish system of automated vial, syringe, and cartridge filling line for the cGMP multi-product production of potent and targeted parenteral pharmaceuticals will take place over the course of 2026. Last but not least, year-to-date, we've added 8 new clients to our CDMO network, mostly for Maple Grove site in Minnesota. Newly added order backlog in 2025 increased to US$138 million. Majority of the contracts, in value, belongs to Canadian site and sterile injectable facility with orders from anchor new clients. On pharma sales side, specialty pharma business significantly outperformed expectations, with the vigabatrin franchise achieving double digit growth in market share. In the second half of the year, we plan to continue investing in channel marketing and strengthening engagement with key stakeholders on the payer side. The revenue mix between specialty pharma and generics reached 35% vs. 65% during the quarter, marking Bora's official transition into a specialty pharma company. Moving forward, we will focus on strengthening our presence in Ready-to-Use forms of dosages in the rare and underserved DEE (Developmental and Epileptic Encephalopathies) space through both in-licensing and proprietary R&D, enabling more efficient resource allocation and return in a market where me-too products have been under increasing pressure. This is part of Bora's ongoing transformation toward a more white-glove, service-oriented model across both pharma sales and CDMO, sharpening our strategic focus on high-demand, value-driven markets to scale, integrate, and synergize' 2Q2025 Operational Achievements & Full Year Outlook Global CDMO Operations Global CDMO Operations (excluding internal orders) revenues arrived at NT$1.59 billion in the second quarter, up 14.8% YoY and representing approximately 32.7% of total revenue. Including internal orders, CDMO revenue reached NT$5.01 billion. A total of 548 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 32%. Bora continues to execute on expanding this customer base to enhance business visibility and stability. · In 1H25, the small molecule and sterile CDMO pipeline added US$138 million in backlog, marking historic high. · While the Company ramps up its Maple Grove site, it is seeing encouraging momentum - clinical-stage clients are transitioning to long-term strategic partnerships. In parallel, Bora observes a steady uptick in contract signings from pharmaceutical companies looking to secure US domestic manufacturing. Discussions remain active with potential anchor clients and the Company is planning the initiation of small molecule packaging line build-out as the first step in our capacity pre-sell strategy. · Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients with half of the potential deals from US clients. Pharma Sales Operations Pharma Sales Operations revenue reached NT$3.26 billion, down 10.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 67.0% of total revenues. · Bora identified a shift from DRE (Drug Resistant Epilepsy) to DEE (Developmental and Epileptic Encephalopathies) in the epilepsy market since the acquisition of Upsher-Smith and validated, through field work of sales and marketing, that legacy compounds fall short in addressing the significant unmet needs in this segment. Approved treatments were only available for epilepsies related to Dravet Syndrome, Lennox-Gastaut Syndrome, TSC (Tuberous Sclerosis Complex) and CDKL5 deficiency at the moment, meaning more NCEs will come in the near future, further enlarging the addressable market. The Company expects to capture the sizable opportunities of approximately US$ 10 billion in the next 3 to 5 years building a sound pipeline with Ready-to-Use 505(b)(2) such as Stiripentol, USL551, and at least 2 more compounds. Bora continues to await regulatory approval for 3 high-value generics in our pipeline in the remainder of the year. Recent Investor Conference Bora will host an English online earnings call at 6:00 p.m. Taiwan time on Aug. 8, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:30 p.m. on Aug. 12, 2025. Both events will cover the company's Q2'25 financial and business results and outlook. 🔗 English Online Earnings Presentation Link: Bora will participate in the Daiwa Consumer and Healthcare Conference on Sept. 3-4 in Hong Kong and Goldman Sachs CDMO Day on Sept. 16-17 in Singapore. For 1:1 meetings with management, please contact your Daiwan and Goldman Sachs representative. Bora 2025 Earnings Schedule Q3 2025: Expected in the 3rd week of November 2025 Q4 2025: Expected in the 2nd week of March 2026 Hashtag: #BoraPharmaceuticals The issuer is solely responsible for the content of this announcement. About Bora: Founded in 2007, Bora Pharmaceuticals ('Bora' or 'the Company', is a leading pharmaceutical services company with a vision and goal of 'Contributing to Better Health All Over the World'. Operating under a 'Dual Engine' model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, please visit: Disclaimer: This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
